On November 2 2009 Endotis Pharma announced the formation of a strategic alliance with Catalent Pharma Solutions. The two companies will collaborate exclusively to develop certain oral formulations of small-glyco drugs and are now focusing on the preclinical development of Endotis’ EP37151 compound. EP37151 is a first in-class oral synthetic oligosaccharide anticoagulant which, as an indirect factor Xa inhibitor, acts via antithrombin activation. The companies expect to initiate a Phase I clinical trial programme during the second quarter of 2010.
November 3, 2009...10:47 am
Alliance between Endotis Pharma and Catalent Pharma Solutions
Jump to Comments
